A recent commentary published in the New England Journal of Medicine on April 9 highlights preclinical evidence that a targeted diet, combined with a polyamine-blocking drug, may encourage aggressive neuroblastoma cells in mice to mature rather than multiply.
The topic is important because neuroblastoma is one of the most lethal cancers affecting children. Researchers are exploring whether dietary changes could improve cancer treatment outcomes. While some studies suggest that altering nutrition can influence tumor metabolism and response to therapy, there is still a gap between these findings and clinical practice.
The commentary describes research using a mouse model of MYCN-driven neuroblastoma. In this study, scientists restricted certain amino acids from the diet while also giving eflornithine, a drug that blocks polyamine production. Polyamines are necessary for cell growth, and MYCN-driven tumors depend on them. Eflornithine alone has shown limited success as a single treatment but has received pre-approval for reducing relapse risk in neuroblastoma.
By removing proline and arginine—amino acids that help make ornithine, which leads to polyamines—from the diet, researchers found they could starve tumors of key building blocks while eflornithine stopped their conversion into polyamines. The study revealed that although tumors had high levels of proline, they still needed outside sources of ornithine and arginine because they lacked enough enzyme activity to convert proline efficiently.
Polyamine depletion led to changes inside tumor cells: it interfered with how ribosomes translated proteins needed for cell division but allowed those related to cell differentiation to be made more easily. This caused cancer cells to stop dividing and become more mature. Interestingly, blocking hypusination—a process thought important in this mechanism—did not produce the same effect; instead, it was the lack of polyamines themselves that drove these changes.
Researchers say these results offer proof-of-concept that metabolic interventions might prompt differentiation in pediatric cancers like neuroblastoma. They also note this strategy could apply beyond just this disease if further studies confirm its effects.
